Skip to main

Medicare now covers treatment with new Alzheimer's drugs, including LEQEMBI. To learn more, Medicare linkclick hereMedicare linktap here.

leh kem' bee LEQEMBI Your browser does not support the audio element. speaker speaker speaker active
leh kan' uh mab lecanemab Your browser does not support the audio element. speaker speaker speaker active

For US residents only

  • Important Safety
    Information
  • Prescribing
    Information
  • Medication
    Guide
  • Healthcare
    Provider Site
LEQEMBI
Eisai Patient Support: 1-833-453-7362
  • About
    LEQEMBI
    • Diagnosing Alzheimer's disease
    • How does LEQEMBI work?
    • LEQEMBI clinical study results
    • LEQEMBI safety
  • Getting started
    with LEQEMBI
    • LEQEMBI infusions
    • Infusion tips
  • Support &
    resources
    • Eisai Patient Support
    • Downloadable resources
    • Infusion Companion
    • Advocacy organizations
  • Sign up for
    more information
  • Eisai Patient Support
    1-833-453-7362
  • Healthcare Provider Site
  • LEQEMBI
    leh kem' bee
    Your browser does not support the audio element. speaker speaker active
    lecanemab
    leh kan' uh mab
    Your browser does not support the audio element. speaker speaker active
Kay, who is living with Alzheimer’s disease, smiling arm in arm with Jennyfer, her care partner

Site map

Kay T.Living with
Alzheimer’s disease

Jennyfer R.Caring for Kay

  • About LEQEMBI
  • Diagnosing Alzheimer’s disease
  • How does LEQEMBI work?
  • LEQEMBI clinical study results
  • LEQEMBI safety
  • Getting started with LEQEMBI
  • LEQEMBI infusions
  • Infusion tips
  • Support & resources
  • Eisai Patient Support
  • Downloadable resources
  • Infusion Companion
  • Advocacy organizations
  • Sign up for more information

Important Safety Information

What is LEQEMBI?

EXPAND COLLAPSE

Important Safety Information

What is the most important information I should know about LEQEMBI?

LEQEMBI can cause serious side effects including:

  • Amyloid Related Imaging Abnormalities or “ARIA”. ARIA is a side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA is most commonly seen as temporary swelling in areas of the brain that usually resolves over time. Some people may also have small spots of bleeding in or on the surface of the brain, and infrequently, larger areas of bleeding in the brain can occur. Most people with this type of swelling in the brain do not get symptoms, however some people may have symptoms, such as:

    – headache

    – confusion

    – dizziness

    – vision changes

    – nausea

    – difficulty walking

    – seizures

What is LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with Alzheimer’s disease.

Do not receive LEQEMBI if you have serious allergic reactions to lecanemab-irmb or to any of the ingredients in LEQEMBI.

Some people have a genetic risk factor (homozygous apolipoprotein E gene carriers) that may cause an increased risk for ARIA. Talk to your healthcare provider about testing to see if you have this risk factor.

Some medicines can increase the risk for larger areas of bleeding in the brain in patients taking LEQEMBI. Talk to your healthcare provider to see if you are on any medicines that increase this risk.

Your healthcare provider will do magnetic resonance imaging (MRI) scans before and during your treatment with LEQEMBI to check you for ARIA.

Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above.

Before receiving LEQEMBI, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. It is not known if LEQEMBI will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with LEQEMBI.

  • are breastfeeding or plan to breastfeed. It is not known if lecanemab-irmb (the active ingredient in LEQEMBI) passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while receiving LEQEMBI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin). Ask your healthcare provider for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of LEQEMBI?

LEQEMBI can cause serious side effects, including:

  • See above "What is the most important information I should know about LEQEMBI?"

  • Serious allergic reactions. Swelling of the face, lips, mouth, or tongue, hives, or difficulty breathing have happened during a LEQEMBI infusion. Tell your healthcare provider if you have any symptoms of a serious allergic reaction during or after LEQEMBI infusion.

  • Infusion-related reactions. Infusion-related reactions are a common side effect which can be serious. Tell your healthcare provider right away if you get these symptoms during an infusion of LEQEMBI:

    – fever

    – flu-like symptoms (chills, body aches, feeling shaky and joint pain)

    – nausea

    – vomiting

    – dizziness or lightheadedness

    – changes in your heart rate or feeling like your chest is pounding

    – difficulty breathing or shortness of breath

If you have an infusion-related reaction, your healthcare provider may give you medicines before your LEQEMBI infusions to decrease your chance of having an infusion-related reaction. These medicines may include antihistamines, anti-inflammatory medicines, or steroids.

The most common side effects of LEQEMBI include:

  • infusion-related reactions

  • swelling in areas of the brain, with or without small spots of bleeding in or on the surface of the brain (ARIA)

  • headache

These are not all the possible side effects of LEQEMBI. Call your doctor for more information and medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the Prescribing Information including Boxed WARNING, and Medication Guide for LEQEMBI.

Patients shown are not taking LEQEMBI.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries. This Website contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for your, or your loved ones’, personal medical needs. Individual responses to treatment may vary.

  • About Eisai
  • Privacy Statement
  • Site Map
  • Legal Notices
Eisai logo
Biogen logo

© 2023 Eisai Inc. and Biogen.
LEQE-US2332 July 2023
All trademarks are the property of their respective owners.
LEQEMBI® is a registered trademark of Eisai R&D Management Co., Ltd.
LEQEMBI Companion™ is a trademark of Eisai R&D Management Co., Ltd.

This site is for US healthcare providers only.

Select “Continue” to verify that you are a US healthcare professional or “Cancel” to return to the previous page.

I UNDERSTAND, let's proceed

You are now leaving LEQEMBI.com.

Eisai Inc. does not endorse the following website, nor does Eisai Inc. review the information contained on the following website for content, accuracy, or completeness.

I UNDERSTAND, let's proceed